-- Aclaris Therapeutics (ACRS) has an average rating of buy and mean price target of $8.94, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)